AML - Acute myeloid leukemia Back

External References: Wikipedia National Cancer Institute Google Scholar

iCoMut Beta for


Highly significantly mutated genes
FLT3
53 patients (27%)
DNMT3A
51 patients (26%)
NPM1
34 patients (17%)
IDH2
20 patients (10%)
IDH1
19 patients (9%)
TET2
17 patients (8%)
RUNX1
17 patients (8%)
TP53
16 patients (8%)
NRAS
15 patients (7%)
WT1
12 patients (6%)
PTPN11
10 patients (5%)
U2AF1
8 patients (4%)
KRAS
8 patients (4%)
KIT
8 patients (4%)
SMC3
7 patients (3%)
STAG2
6 patients (3%)
Significantly mutated genes
CEBPA
13 patients (6%)
SMC1A
7 patients (3%)
PHF6
6 patients (3%)
RAD21
6 patients (3%)
ASXL1
5 patients (2%)
SFRS2
4 patients (2%)
PAPD5
3 patients (1%)
EZH2
3 patients (1%)
MXRA5
3 patients (1%)
PDSS2
2 patients (1%)
Genes near significance
GATA2
4 patients (2%)
KDM6A
3 patients (1%)
TYW1
3 patients (1%)
RBBP4
2 patients (1%)
Click on a gene to see details.

Notes


• Gene name color indicates: known cancer genes | highly compelling novel candidate cancer genes | other candidates

Data details


Mutation list for AML
Q-Q plots for AML